BioMarin Announces Second Quarter 2015 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results
August 5, 2015 6:44 AM EDTWedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $139.00 (from $130.00), following Q2 earnings. Q2 revenues of $250.5MM beat consensus ($218.2MM). GAAP-EPS of $(0.55) was below consensus of $(0.53) due to high Op-Ex.
Analyst Liana Moussatos commented, "Q2... More
Piper Jaffray Raises Price Target on BioMarin Pharma (BMRN) to $168 Following 2Q Results
August 4, 2015 8:41 AM EDTPiper Jaffray reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $168.00 (from $163.00), following 2Q15 earnings results. Analyst Joshua Schimmer said that the results beat top and bottom line driven primarily by lumpy Naglazyme purchasing and reiterated... More
BioMarin (BMRN) PT Raised to $173 at Nomura; Increasingly Confident on Drisapersen
August 4, 2015 7:24 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $173.00 (from $163.00) following Q2 results, saying they are increasingly confident on Drisapersen.
Somaiya commented, "We are raising our BMRN TP to $173 from $163 following 2Q earnings which... More
BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
August 3, 2015 4:04 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.51), $0.02 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $250 million versus the consensus estimate of $218.16 million.
Total Revenue Growth... More